Moxifloxacin Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin exerts its antibacterial effect by inhibiting two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are required for DNA supercoiling, replication, and transcription. By blocking their activity, the drug prevents bacterial DNA synthesis, leading to rapid bacterial cell death.

The dosing regimen for Moxifloxacin Kabi is determined by the prescribing clinician based on the infection type, severity, patient age, weight, renal and hepatic function, and local antimicrobial guidelines. Healthcare professionals should follow the approved prescribing information and adjust the dose as clinically indicated.

Moxifloxacin is classified as pregnancy category unknown. Use during pregnancy or lactation should be considered only when the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate the individual clinical situation and discuss possible alternatives with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and enhanced activity against atypical respiratory pathogens compared with older fluoroquinolones such as ciprofloxacin. It also has a lower propensity for inducing resistance in certain strains. However, safety considerations such as QT prolongation and tendon toxicity remain similar across the class, requiring careful patient selection.

Moxifloxacin Kabi must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Prior to administration, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration.

Moxifloxacin Kabi is given as an intravenous infusion. The recommended infusion rate is typically over 60 minutes, but the exact rate and dilution volume are determined by the prescriber based on patient condition and institutional protocols. Administration should be performed by qualified healthcare personnel using aseptic technique.

Serious adverse events include tendon rupture or tendinitis, especially in the Achilles tendon; Clostridioides difficile‑associated colitis; severe hypersensitivity reactions such as anaphylaxis; Stevens‑Johnson syndrome or toxic epidermal necrolysis; hepatic failure; and cardiac arrhythmias like torsades de pointes due to QT interval prolongation. Prompt medical attention is required if any of these occur.

Moxifloxacin Kabi is contraindicated in patients with a known hypersensitivity to moxifloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled epilepsy, or those taking other medications that significantly prolong the QT interval without appropriate monitoring.